Can a chemo pill mop up hidden breast cancer cells?

NCT ID NCT07631052

First seen Jun 09, 2026 · Last updated Jun 24, 2026 · Updated 4 times

Summary

This phase 2 trial tests whether the chemotherapy pill capecitabine can eliminate tiny amounts of cancer DNA still present in the blood after standard treatment for early-stage ER+/HER2- breast cancer. About 15 patients whose blood tests show residual cancer DNA will take capecitabine for up to 12 months. The main goal is to see if the cancer DNA becomes undetectable, which might lower the chance of the cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE I are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UHN - Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 1Z5, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Capecitabine (chemotherapy pill)

What this could lead to

If successful, this could offer a way to eliminate lingering cancer cells detected by a blood test, potentially reducing the risk of cancer returning.

What could go wrong

This is a very small early-phase trial with only 15 participants, so results may not apply broadly. Capecitabine can cause side effects like hand-foot syndrome and digestive issues.

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.